{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:24:07Z","timestamp":1786983847997,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.abd.2021.11.002","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T21:16:25Z","timestamp":1657833385000},"page":"566-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-9806","authenticated-orcid":false,"given":"Ilteris","family":"Oguz Topal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-5821","authenticated-orcid":false,"given":"Sevim","family":"Baysak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1354-7123","authenticated-orcid":false,"given":"\u0130lknur K\u0131van\u00e7","family":"Altunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-6901","authenticated-orcid":false,"given":"Asude","family":"Kara Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-0166","authenticated-orcid":false,"given":"Eylem Emel","family":"Ar\u0131kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9136-7021","authenticated-orcid":false,"given":"Ezgi","family":"\u00d6zkur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-1573","authenticated-orcid":false,"given":"Sema","family":"Aytekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-5209","authenticated-orcid":false,"given":"Bilal","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-2543","authenticated-orcid":false,"given":"Tu\u011fba","family":"\u00d6zk\u00f6k Akbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-1316","authenticated-orcid":false,"given":"Filiz","family":"Topalo\u011flu Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-8274","authenticated-orcid":false,"given":"Ay\u015fe Serap","family":"Karada\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2021.11.002_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"J Investig Dermatol Symp Proc."},{"key":"10.1016\/j.abd.2021.11.002_bib0010","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: epidemiology","volume":"25","author":"Gudjonsson","year":"2007","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5152\/tdd.2011.16","article-title":"Evalution of Clinical and Sociodemograpic Features of Patients with Psoriasis in the Konya Region","volume":"5","author":"Aykol","year":"2011","journal-title":"Turk J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4274\/tdd.1478","article-title":"The Evaluation of the Sociodemografic and Clinical Features of Patients with Psoriasis","volume":"7","author":"Turan","year":"2013","journal-title":"Turk J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0030","first-page":"1767","article-title":"Profile of secukinumab in the treatment of psoriasis: current perspectives","volume":"11","author":"Roman","year":"2015","journal-title":"Ther Clin Risk Manag."},{"issue":"7","key":"10.1016\/j.abd.2021.11.002_bib0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CCID.S67534","article-title":"Targeting of interleukin-17 in the treatment of psoriasis","volume":"15","author":"L\u00f8nnberg","year":"2014","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.abd.2021.11.002_bib0045","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.abd.2021.11.002_bib0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs."},{"key":"10.1016\/j.abd.2021.11.002_bib0055","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"The Br J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0060","first-page":"1","article-title":"Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature","volume":"22","author":"Abrouk","year":"2017","journal-title":"Skin Therapy Lett."},{"key":"10.1016\/j.abd.2021.11.002_bib0065","first-page":"S7","article-title":"Secukinumab: Review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR","volume":"9","author":"Armstrong","year":"2016","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.abd.2021.11.002_bib0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2019.02.062","article-title":"A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients","volume":"81","author":"Ortiz-Salvador","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0080","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaad.2017.11.036","article-title":"Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study","volume":"78","author":"Georgakopoulos","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0085","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12550","article-title":"Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study","volume":"30","author":"Schwensen","year":"2017","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2021.11.002_bib0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2021.11.002_bib0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/1346-8138.13900","article-title":"Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study","volume":"44","author":"Wu","year":"2017","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","article-title":"Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation","volume":"18","author":"Galluzzo","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.abd.2021.11.002_bib0105","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1684\/ejd.2020.3878","article-title":"Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients","volume":"30","author":"Huang","year":"2020","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0110","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13006","article-title":"Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study","volume":"32","author":"Rompoti","year":"2019","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2021.11.002_bib0115","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319843756","article-title":"Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement","volume":"10","author":"Ger","year":"2019","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.abd.2021.11.002_bib0120","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/1346-8138.14145","article-title":"Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience","volume":"45","author":"Momose","year":"2018","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14044","article-title":"Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study","volume":"33","author":"Carpentieri","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2021.11.002_bib0130","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1111\/ced.13999","article-title":"Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance","volume":"44","author":"Ferri\u00e8res","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.abd.2021.11.002_bib0135","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CM9.0000000000001510","article-title":"Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study","volume":"134","author":"Zhao","year":"2021","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.abd.2021.11.002_bib0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjd.18623","article-title":"Secukinumab for patients failing previous tumour necrosis factor-\u03b1 inhibitor therapy: results of a randomized open-label study (SIGNATURE)","volume":"183","author":"Warren","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0145","article-title":"Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study","volume":"33","author":"Demir","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2021.11.002_bib0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjd.15414","article-title":"Candida infections and interleukin-17 inhibitors used in dermatology","volume":"177","author":"Hay","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0160","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1346-8138.14761","article-title":"Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study","volume":"46","author":"Okubo","year":"2019","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09546634.2018.1530437","article-title":"Candida infections in psoriatic patients on anti-IL17 therapy: a case series","volume":"29","author":"Papini","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2021.11.002_bib0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2021.11.002_bib0175","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/kev263","article-title":"Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab","volume":"54","author":"\u010carija","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059622001209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059622001209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:40:49Z","timestamp":1759794049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059622001209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0365059622001209"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2021.11.002","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2021.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.","name":"copyright","label":"Copyright"}]}}